Cyclopharm has secured a significant multi-site agreement with the University of Pennsylvania Health System, marking a major step in its US expansion with installations across 11 clinical locations.
- Multi-site agreement covers 11 UPHS locations in Pennsylvania and New Jersey
- Immediate Technegas® installations at two high-volume UPHS centres
- Contract includes recurring consumables and service revenue over three years
- Strategic foothold in a leading US academic health system with national influence
- Potential for further expansion within UPHS and affiliated networks
A Landmark US Expansion
Cyclopharm Limited (ASX:CYC) has taken a major stride in its US commercial rollout by securing a multi-site agreement with the University of Pennsylvania Health System (UPHS). This deal covers 11 clinical locations across Pennsylvania and New Jersey, including immediate installations at two prominent centres: the Hospital of the University of Pennsylvania and the Perelman Center for Advanced Medicine.
The Hospital of the University of Pennsylvania is ranked among the top 20 hospitals in the US and is the leading hospital in Pennsylvania, making this agreement a significant endorsement of Cyclopharm’s Technegas® technology. The UPHS network’s stature as a premier academic health system adds considerable weight to Cyclopharm’s presence in the mid-Atlantic corridor.
Strategic and Financial Implications
The agreement is structured to generate recurring revenue through consumables used per patient procedure and annual service fees, underpinning a sustainable business model beyond initial installations. The initial contract term spans three years, with potential for expansion to additional UPHS-affiliated sites, signalling a pathway for deeper institutional penetration.
By establishing Technegas® across multiple sites within a single integrated health system, Cyclopharm gains regional density that could accelerate adoption of its technology not only for pulmonary embolism diagnosis but also for broader respiratory and oncology-related applications. This aligns with Cyclopharm’s strategy of progressing from isolated installations to system-wide adoption within large US healthcare networks.
Broader Market Momentum
UPHS’s role as a key opinion leader in clinical research and advanced imaging provides Cyclopharm with a flagship reference cluster in the Philadelphia market, enhancing its commercial leverage for further Independent Delivery Network expansions. The deal underscores Cyclopharm’s accelerating execution in the US, focused on building regional density and establishing leading reference sites.
CEO James McBrayer highlighted the significance of the agreement, noting it as a milestone that will drive scalable, recurring revenue growth and improve operating leverage as utilisation increases. The partnership with a high-profile academic system is expected to bolster Cyclopharm’s profile and adoption across the mid-Atlantic and Northeast regions.
Bottom Line?
Cyclopharm’s UPHS deal sets the stage for deeper US market penetration and recurring revenue growth.
Questions in the middle?
- What are the expected timelines and financial impacts of the remaining nine site installations?
- How quickly will Technegas® adoption expand beyond pulmonary embolism to other respiratory conditions within UPHS?
- Will Cyclopharm secure similar multi-site agreements with other major US health systems following this deal?